Recommendations made
pediatrician - Dr. Victоr Аbdоw
Rоckville, МD, USА.
Is it allowed to take Tiludronate Sodium during lactation? |
|
It is composed by bisphosphonates. Most bisphosphonates are acidic compounds that achieve low plasma concentration. Both features make it unlikely excretion into the milk in clinically significant amount. Intestinal absorption of bisphosphonates is very low even during fasting and is considered negligible in the presence of milk due to formation with the calcium of non absorbable compounds. Among bisphosponate preparations, Tiludronate and Zoledronate have the longest half-lives period of elimination and thus they are the less indicated to take while breastfeeding. A latest update no published data were found on excretion in the breast milk. Until more data about this drug regarding breastfeeding is available, safer known alternatives (pamidronate) should be of choice, especially in the neonatal period and in case of prematurity. |
|
Would you like to ask something else about Tiludronate Sodium ? |
Types of risk
VERY LOW RISK
It is allowed while breastfeeding. It is not dangerous for a baby. It is moderately safe. more...
LOW RISK PROBABLE
Possible presence in breast milk is allowed. Follow the doctor's recommendation. more...
HIGH RISK PROBABLE
An unsafe drug, it is necessary to assess the risks while taking. Use safer analogs. more...
VERY HIGH RISK
It is not recommended. You need to stop breastfeeding or choose a safe analog. more...
Analogues
Synonyms
Trade Names
The main trade names in different countries containing in its composition Tiludronate Sodium:Scientific literature
The level of risk for breastfeeding is confirmed in these scientific publications:- http://www.ncbi.nlm.nih.gov/pubmed/25404594
- http://www.ncbi.nlm.nih.gov/pubmed/22281884
- http://www.hormones.gr/pdf/HORMONES%202011-280-291.pdf
- http://www.ncbi.nlm.nih.gov/pubmed/19533208
- http://www.ncbi.nlm.nih.gov/pubmed/19175968
- http://www.ncbi.nlm.nih.gov/pubmed/14594094
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2214129/pdf/14594094.pdf